Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (391-400 of 463) with videos related to

Pageof 47
Sort By:
Inflammatory Bowel Diseases|April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC StudiesStefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Gastroenterology|June 23, 2026
Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control TrialGregory Rosenfeld, Neeraj Narula, Yvette Leung, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
The Journal of Experimental Medicine|December 12, 2024
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitisJoan Shang, Diane Marie Del Valle, Graham J Britton, et al.
Gut|August 9, 2024
Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease familiesJonathan P Jacobs, Elizabeth A Spencer, Drew S Helmus, et al.
Nature Immunology|July 30, 2024
A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycanJoana Gaifem, Cláudia S Rodrigues, Francesca Petralia, et al.
The Journal of Clinical Investigation|May 2, 2023
Selective IgA2 deficiency in a patient with small intestinal Crohn's diseasePablo Canales-Herrerias, Yolanda Garcia-Carmona, Joan Shang, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Gastroenterology|December 12, 2018
Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative ColitisSudarshan Paramsothy, Shaun Nielsen, Michael A Kamm, et al.
The Lancet. Gastroenterology & Hepatology|April 5, 2025
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial designSailish Honap, Nelly Agrinier, Joana Torres, et al.
Pageof 47

Showing results (391-400 of 463) with videos related to

Sort By:
Pageof 47
Inflammatory Bowel Diseases|April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC StudiesStefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Gastroenterology|June 23, 2026
Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control TrialGregory Rosenfeld, Neeraj Narula, Yvette Leung, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
The Journal of Experimental Medicine|December 12, 2024
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitisJoan Shang, Diane Marie Del Valle, Graham J Britton, et al.
Gut|August 9, 2024
Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease familiesJonathan P Jacobs, Elizabeth A Spencer, Drew S Helmus, et al.
Nature Immunology|July 30, 2024
A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycanJoana Gaifem, Cláudia S Rodrigues, Francesca Petralia, et al.
The Journal of Clinical Investigation|May 2, 2023
Selective IgA2 deficiency in a patient with small intestinal Crohn's diseasePablo Canales-Herrerias, Yolanda Garcia-Carmona, Joan Shang, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Gastroenterology|December 12, 2018
Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative ColitisSudarshan Paramsothy, Shaun Nielsen, Michael A Kamm, et al.
The Lancet. Gastroenterology & Hepatology|April 5, 2025
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial designSailish Honap, Nelly Agrinier, Joana Torres, et al.
Pageof 47